Impact of radiation-induced toxicities on quality of life of patients treated for head and neck cancer
- PMID: 33892023
- DOI: 10.1016/j.radonc.2021.04.011
Impact of radiation-induced toxicities on quality of life of patients treated for head and neck cancer
Abstract
Purpose: The aim of this study is to establish the relative impact of physician-rated toxicities and patient-rated symptoms in head and neck cancer (HNC) on quality of life (QOL) and to weigh the various toxicities and symptoms during treatment plan optimization and selection.
Materials and methods: This prospective cohort study comprised 1083 HNC patients (development: 750, validation: 333) treated with definitive radiotherapy with or without chemotherapy. Clinical factors were scored at baseline. Physician-rated and patient-rated outcome measures and QOL (EORTC QLQ-HN35 and QLQ-C30) were prospectively scored at baseline and 6, 12, 18 and 24 months after radiotherapy. The impact of 20 common toxicities and symptoms (related to swallowing, salivary function, speech, pain and general complaints) on QOL (0-100 scale) was established for each time point by combining principal component analysis and multivariable linear regression.
Results: Radiation-induced toxicities and symptoms resulted in a significant decline in QOL of patients with 12.4 ± 12.8 points at 6 months to 16.6 ± 17.1 points at 24 months. The multivariable linear models described the QOL points subtracted for each toxicity and symptom after radiotherapy. For example, xerostomia and weight loss had a significant but minor effect (on average -0.5 and -0.6 points) while speech problems and fatigue had a much greater impact (on average -11.9 and -17.4 points) on QOL. R2 goodness-of-fit values for the QOL models ranged from 0.64 (6 months) to 0.72 (24 months).
Conclusion: The relative impact of physician-rated toxicities and patient-rated symptoms on QOL was quantified and can be used to optimize, compare and select HNC radiotherapy treatment plans, to balance the relevance of toxicities and to achieve the best QOL for individual patients.
Keywords: Dose optimisation; Head and neck cancer; NTCP; Quality of life; Toxicities.
Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Quality of life and toxicity guided treatment plan optimisation for head and neck cancer.Radiother Oncol. 2021 Sep;162:85-90. doi: 10.1016/j.radonc.2021.06.035. Epub 2021 Jul 5. Radiother Oncol. 2021. PMID: 34237344
-
Residual deficits in quality of life one year after intensity-modulated radiotherapy for patients with locally advanced head and neck cancer: Results of a prospective study.Strahlenther Onkol. 2015 Jun;191(6):501-10. doi: 10.1007/s00066-015-0824-4. Epub 2015 Mar 8. Strahlenther Onkol. 2015. PMID: 25747264 Clinical Trial.
-
Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes.Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):935-40. doi: 10.1016/j.ijrobp.2012.08.030. Epub 2012 Oct 3. Int J Radiat Oncol Biol Phys. 2013. PMID: 23040224 Free PMC article.
-
Outcomes of xerostomia-related quality of life for nasopharyngeal carcinoma treated by IMRT: based on the EORTC QLQ-C30 and H&N35 questionnaires.Expert Rev Anticancer Ther. 2015 Jan;15(1):109-19. doi: 10.1586/14737140.2015.961427. Epub 2014 Sep 18. Expert Rev Anticancer Ther. 2015. PMID: 25231774 Review.
-
Nutrition impact symptoms and associated outcomes in post-chemoradiotherapy head and neck cancer survivors: a systematic review.J Cancer Surviv. 2018 Aug;12(4):479-494. doi: 10.1007/s11764-018-0687-7. Epub 2018 Mar 20. J Cancer Surviv. 2018. PMID: 29556926
Cited by
-
Comment on Prospective Study to Compare Efficacy of Conventional Chemoradiotherapy with Hypofractionated Chemoradiotherapy in Locally Advanced Carcinoma of Oropharynx.Asian Pac J Cancer Prev. 2024 Feb 1;25(2):367-368. doi: 10.31557/APJCP.2024.25.2.367. Asian Pac J Cancer Prev. 2024. PMID: 38415519 Free PMC article. No abstract available.
-
The epidemic of human papillomavirus virus-related oropharyngeal cancer: current controversies and future questions.Infect Agent Cancer. 2024 Nov 28;19(1):58. doi: 10.1186/s13027-024-00616-0. Infect Agent Cancer. 2024. PMID: 39609676 Free PMC article. Review.
-
The course of swallowing problems in the first 2 years after diagnosis of head and neck cancer.Support Care Cancer. 2022 Nov;30(11):9527-9538. doi: 10.1007/s00520-022-07322-w. Epub 2022 Aug 30. Support Care Cancer. 2022. PMID: 36040669 Free PMC article.
-
Acute Impact of Cancer Treatment on Head and Neck Cancer Patients: FIT4TREATMENT.Cancers (Basel). 2022 May 30;14(11):2698. doi: 10.3390/cancers14112698. Cancers (Basel). 2022. PMID: 35681678 Free PMC article.
-
Differential Radiomodulating Action of Olea europaea L. cv. Caiazzana Leaf Extract on Human Normal and Cancer Cells: A Joint Chemical and Radiobiological Approach.Antioxidants (Basel). 2022 Aug 19;11(8):1603. doi: 10.3390/antiox11081603. Antioxidants (Basel). 2022. PMID: 36009322 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical